Indevus Announces Agreement With Teva To Develop Pagoclone For The Treatment Of Stuttering

Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone.